Rare diseases (RD) are typically complex, chronic, often multisystem, and frequently genetic disorders associated with significant morbidity and mortality. They affect up to 6–8% of the population and 30% of Australians with RD waited between 5 to 30 or more years for a diagnosis.1 There are now game-changing clinical genomic approaches that are reducing these diagnostic odysseys. However, parallel to hitherto unachieved improvements in RD diagnosis is the known and recently demonstrated risk2 that Indigenous Australians will not enjoy the same diagnostic opportunities as non-Indigenous Australians.
This health care gap is due to the absence of Indigenous genomic reference information. Genomic references provide a context for understanding the normal variation in the four biological letters — A, C, T and G — of our DNA code. They are fundamental to determine whether genetic variants identified in an individual are disease causing (pathogenic) or otherwise. Rare variations are often population specific and rare genetic variants are disproportionately important as the cause of rare and other diseases.3 Therefore, reference genomic data representative of the population to which the individual belongs are crucial for separating real from spurious findings.
In response to a delay in diagnosing an RD in an Aboriginal family in remote Western Australia — due to the lack of a suitable genomic reference — an initial solution was to deal with this urgent clinical need. Whole exome sequencing had been performed in Aboriginal people in WA, from locally relevant regions, on research cohorts unselected for RD. In these studies, which proceeded with deep culturally appropriate community engagement and governance,4 participants agreed to deposition of their genomic data in a public database. In accordance with participant consent, and to prevent a potential diagnostic delay and health care inequity, applications can now be made to access these data for clinical diagnostic work in the health system. This has been applied to clinical genomic test interpretation in WA.
This rapid clinical translation is a first step to closing the clinical genomic gap and must be followed by the generation of further Indigenous reference data that include other Australian regions.
- 1. Molster C, Urwin D, Di Pietro L, et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet Journal of Rare Diseases 2016; 11: 30.
- 2. Baynam G, Overkov A, Davis M, et al. A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces. Am J Med Genet A 2015; 167: 1659-1667.
- 3. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753.
- 4. Tang D, Anderson D, Francis RW, et al. Reference genotype and exome data for an Australian Aboriginal population: a reference panel for health-based research. Sci Data 2016; 3: 160023. http://www.nature.com/articles/sdata201623 (accessed Aug 2016).
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.